{"id":28377,"date":"2025-07-03T12:19:56","date_gmt":"2025-07-03T10:19:56","guid":{"rendered":"https:\/\/www.clinica-sante.com\/ro\/?page_id=28377"},"modified":"2026-03-24T14:55:08","modified_gmt":"2026-03-24T12:55:08","slug":"programul-national-de-oncologie","status":"publish","type":"page","link":"https:\/\/www.clinica-sante.com\/ro\/programul-national-de-oncologie\/","title":{"rendered":"Programul Na\u021bional de Oncologie"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Oferim acces la investiga\u021bii oncologice GRATUITE<\/strong>, ca parte a Programului Na\u021bional de Oncologie, prin intermediul Subprogramului Na\u021bional de Testare Genetic\u0103.<\/p>\n

Clinica Sante face parte din Subprogramul Na\u021bional de Testare Genetic\u0103, oferind pacien\u021bilor diagnostica\u021bi cu anumite afec\u021biuni oncologice acces GRATUIT la investiga\u021bii avansate pentru testarea profilului molecular. Prin implicarea \u00een acest program, ne reafirm\u0103m angajamentul fa\u021b\u0103 de furnizarea unor servicii medicale moderne, de \u00eenalt\u0103 calitate, contribuind activ la \u00eembun\u0103t\u0103\u021birea prognosticului \u0219i \u0219anselor de tratament personalizat \u00een cazul bolilor oncologice complexe.<\/p>\n<\/div>\n\n

\r\n
\r\n

Cuprins<\/p>\r\n <\/div>\r\n

    \r\n
  1. \r\n Importan\u021ba test\u0103rii genetice \u00een oncologie<\/a><\/span>\r\n <\/li>\r\n
  2. \r\n Diagnostic precis. Tratament \u021bintit. Speran\u021b\u0103 real\u0103.<\/a><\/span>\r\n <\/li>\r\n
  3. \r\n Solidari \u00een fa\u021ba diagnosticului oncologic<\/a><\/span>\r\n <\/li>\r\n
  4. \r\n Tipurile de cancer vizate de testarea gratuit\u0103<\/a><\/span>\r\n <\/li>\r\n <\/ol>\r\n <\/div>\r\n \r\n\n\n\n
    \n

    \n 1.<\/span>\n Importan\u021ba test\u0103rii genetice \u00een oncologie <\/h2>\n<\/div>\n\n\n
    \n
    \n \n \n \n <\/g>\n \n \n \n <\/clipPath>\n <\/defs>\n <\/svg>\n\n <\/div>\n
    \n

    <\/h2>\n

    \u00cen ultimele decenii, oncologia a cunoscut o evolu\u021bie rapid\u0103, orient\u00e2ndu-se tot mai mult spre terapii personalizate, adaptate specificului genetic \u0219i molecular al fiec\u0103rui pacient. Tratarea cancerului nu mai \u00eenseamn\u0103 doar administrarea unui tratament \u201estandard\u201d, ci este un proces complex, \u00een care informa\u021biile moleculare joac\u0103 un rol decisiv. Testarea genetic\u0103 ofer\u0103 medicilor oncologi date esen\u021biale despre tipul exact de muta\u021bii genetice implicate \u00een dezvoltarea tumorilor. Astfel, se pot stabili scheme terapeutice mult mai eficiente, cu poten\u021bial redus de efecte adverse \u0219i cu \u0219anse de r\u0103spuns favorabil considerabil \u00eembun\u0103t\u0103\u021bite.<\/p>\n<\/p>\n <\/div>\n<\/div>\n\n\n\n

    \n sus<\/span>\n<\/div>\n\n\n
    \n

    \n 2.<\/span>\n Diagnostic precis. Tratament \u021bintit. Speran\u021b\u0103 real\u0103. <\/h2>\n<\/div>\n\n\n
    \n
    \n \n \n \n <\/g>\n \n \n \n <\/clipPath>\n <\/defs>\n <\/svg>\n\n <\/div>\n
    \n

    <\/h2>\n

    Prin acest program, pacien\u021bii pot avea acces GRATUIT la investiga\u021bii avansate, f\u0103r\u0103 costuri suplimentare.<\/p>\n

    Dac\u0103, \u00een trecut, astfel de teste erau dificil de accesat sau foarte costisitoare, acum, datorit\u0103 unei ini\u021biative na\u021bionale, ace\u0219tia au la dispozi\u021bie sprijinul necesar, pentru un diagnostic precis \u0219i un tratament personalizat. Scopul acestui program este de a le \u00eembun\u0103t\u0103\u021bi calitatea vie\u021bii \u0219i \u0219ansele de recuperare, contribuind, totodat\u0103, la dezvoltarea unei baze \u0219tiin\u021bifice utile pentru viitorul medicinei oncologice.<\/p>\n<\/p>\n <\/div>\n<\/div>\n\n\n\n

    \n sus<\/span>\n<\/div>\n\n\n
    \n

    \n 3.<\/span>\n Solidari \u00een fa\u021ba diagnosticului oncologic <\/h2>\n<\/div>\n\n\n
    \n
    \n \n \n \n <\/g>\n \n \n \n <\/clipPath>\n <\/defs>\n <\/svg>\n\n <\/div>\n
    \n

    <\/h2>\n

    La Clinica Sante, ne-am aliniat tuturor standardelor impuse de acest program, pentru ca pacien\u021bii no\u0219tri s\u0103 aib\u0103 acces la cele mai avansate servicii medicale. Laboratoarele noastre sunt dotate cu tehnologie de ultim\u0103 genera\u021bie, iar echipa este format\u0103 din speciali\u0219ti cu experien\u021b\u0103 \u00een oncologie \u0219i genetic\u0103 medical\u0103, preg\u0103ti\u021bi s\u0103 interpreteze rezultatele cu cea mai mare acurate\u021be<\/p>\n

    Implicarea \u00een acest program reprezint\u0103 un pas firesc\u00a0 – misiunea noastr\u0103 a fost \u00eentotdeauna accea de a facilita accesul la servicii medicale de \u00eenalt\u0103 calitate, cu at\u00e2t mai mult pentru cazurile medicale complexe.<\/p>\n<\/p>\n <\/div>\n<\/div>\n\n\n\n

    \n sus<\/span>\n<\/div>\n\n\n
    \n

    \n 4.<\/span>\n Tipurile de cancer vizate de testarea gratuit\u0103 <\/h2>\n<\/div>\n\n
    \n\n

    \n CANCER COLORECTAL <\/p>\n \n

    \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
    Panel de testare<\/th>\n Teste incluse \u00een panelul de testare<\/th>\n Metoda de lucru<\/th>\n Specimen prob\u0103<\/th>\n Indica\u021bie<\/th>\n Specialit\u0103\u021bi care emit referatul<\/th>\n <\/tr>\n <\/thead>\n \n

    Panelul de teste nr. 1<\/p>\n<\/td>\n\n \n

    MSI\/dMMR (MLH1, MSH2, MSH6, PMS2)<\/p>\n<\/td>\n\n \n

    IHC<\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103<\/p>\n<\/td>\n\n \n

    Pacien\u0163ii nou diagnostica\u0163i cu cancer colorectal, local avansat sau metastazat.<\/p>\n<\/td>\n\n \n

    Oncologie medical\u0103<\/p>\n<\/td>\n\n <\/tr>\n

    Panelul de teste nr. 1<\/p>\n<\/td>\n\n \n

    Mutatii RAS (exonii 2, 3, 4 in KRAS si NRAS)<\/p>\n<\/td>\n\n \n

    PCR<\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103<\/p>\n<\/td>\n\n \n

    Pacien\u0163ii nou diagnostica\u0163i cu cancer colorectal, local avansat sau metastazat.<\/p>\n<\/td>\n\n \n

    Oncologie medical\u0103<\/p>\n<\/td>\n\n <\/tr>\n

    Panelul de teste nr. 1<\/p>\n<\/td>\n\n \n

    NTRK 1,NTRK 2, NTRK 3<\/p>\n<\/td>\n\n \n

    IHC<\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103<\/p>\n<\/td>\n\n \n

    Pacien\u0163ii nou diagnostica\u0163i cu cancer colorectal, local avansat sau metastazat.<\/p>\n<\/td>\n\n \n

    Oncologie medical\u0103<\/p>\n<\/td>\n\n <\/tr>\n

    Panelul de teste nr. 1<\/p>\n<\/td>\n\n \n

    BRAF V600E<\/p>\n<\/td>\n\n \n

    PCR \/NGS <\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103<\/p>\n<\/td>\n\n \n

    \u00cen situa\u0163ia \u00een care rezultatul la testarea Muta\u0163ii RAS (exon 2, 3, 4 \u00een KRAS \u015fi NRAS) este \u00abf\u0103r\u0103 muta\u0163ii\u00bb <\/p>\n<\/td>\n\n \n

    Oncologie medical\u0103<\/p>\n<\/td>\n\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n<\/div>\n\n\n

    \n\n

    \n CANCER BRONHOPULMONAR NSCLC <\/p>\n \n

    \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
    Panel de testare<\/th>\n Teste incluse \u00een panelul de testare<\/th>\n Metoda de lucru<\/th>\n Specimen prob\u0103<\/th>\n Indica\u021bie<\/th>\n Specialit\u0103\u021bi care emit referatul<\/th>\n <\/tr>\n <\/thead>\n \n

    Panelul de teste nr. 1\ufeff<\/span><\/p>\n<\/td>\n\n \n

    Diagnostic de certitudine a carcinomului bronhopulmonar NSCLC\ufeff<\/span><\/p>\n<\/td>\n\n \n

    IHC\ufeff<\/span><\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103\ufeff<\/span><\/p>\n<\/td>\n\n \n

    \ufeff<\/span><\/p>\n<\/td>\n\n \n

    oncologie medical\u0103, pneumologie, chirurgie toracic\u0103, precum \u0219i medicul anatomopatolog care a efectuat examenul histopatologic\ufeff<\/span><\/p>\n<\/td>\n\n <\/tr>\n

    Panelul de teste nr. 2\ufeff<\/span><\/p>\n<\/td>\n\n \n

    EGFR- muta\u0163ii (exonii de la 18 la 21) + BRAF V600E + KRAS G12C – +ALK+ROS-1+ NTRK fuziuni +RET- fuziuni<\/p>\n<\/td>\n\n \n

    NGS\ufeff<\/span><\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103\ufeff<\/span><\/p>\n<\/td>\n\n \n

    Pacien\u0163ii nou diagnostica\u0163i cu NSCLC – non-scuamos \u015fi scuamos nefum\u0103tori, \u00een stadiul metastatic sau local avansat\ufeff<\/span><\/p>\n<\/td>\n\n \n

    oncologie medical\u0103, pneumologie, chirurgie toracic\u0103, precum \u0219i medicul anatomopatolog care a efectuat examenul histopatologic\ufeff<\/span><\/p>\n<\/td>\n\n <\/tr>\n

    Panelul de teste nr. 2\ufeff<\/span><\/p>\n<\/td>\n\n \n

    PD-L1: (22C3 + SP 263+ SP 142) sau (22C3 + SP 263)\ufeff<\/span><\/p>\n<\/td>\n\n \n

    IHC\ufeff<\/span><\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103\ufeff<\/span><\/p>\n<\/td>\n\n \n

    Pacien\u0163ii nou diagnostica\u0163i cu NSCLC – non-scuamos \u015fi scuamos nefum\u0103tori, \u00een stadiul metastatic sau local avansat<\/p>\n

     \ufeff<\/span><\/p>\n<\/td>\n\n \n

    oncologie medical\u0103, pneumologie, chirurgie toracic\u0103, precum \u0219i medicul anatomopatolog care a efectuat examenul histopatologic<\/p>\n

     \ufeff<\/span><\/p>\n<\/td>\n\n <\/tr>\n

    Panelul de teste nr. 3\ufeff<\/span><\/p>\n<\/td>\n\n \n

    PD-L1: (22C3 + SP 263+ SP 142) sau (22C3 + SP 263)\ufeff<\/span><\/p>\n<\/td>\n\n \n

    IHC\ufeff<\/span><\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103\ufeff<\/span><\/p>\n<\/td>\n\n \n

    Pacien\u0163ii nou diagnostica\u0163i cu NSCLC scuamos – fum\u0103tori, \u00een stadiul metastatic sau local avansat\ufeff<\/span><\/p>\n<\/td>\n\n \n

    oncologie medical\u0103, pneumologie, chirurgie toracic\u0103, precum \u0219i medicul anatomopatolog care a efectuat examenul histopatologic\ufeff<\/span><\/p>\n<\/td>\n\n <\/tr>\n

    Panelul de teste nr. 4\ufeff<\/span><\/p>\n<\/td>\n\n \n

    EGFR (muta\u0163ii \u00een exonii de la 18 la 21)\ufeff<\/span><\/p>\n<\/td>\n\n \n

    PCR\ufeff<\/span><\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103\ufeff<\/span><\/p>\n<\/td>\n\n \n

    Pacien\u0163ii nou diagnosticati cu NSCLC, \u00een stadii operabile<\/p>\n<\/td>\n\n \n

    oncologie medical\u0103, pneumologie, chirurgie toracic\u0103, precum \u0219i medicul anatomopatolog care a efectuat examenul histopatologic\ufeff<\/span><\/p>\n<\/td>\n\n <\/tr>\n

    Panelul de teste nr. 4\ufeff<\/span><\/p>\n<\/td>\n\n \n

    ALK EML 4\ufeff<\/span><\/p>\n<\/td>\n\n \n

    IHC\ufeff<\/span><\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103\ufeff<\/span><\/p>\n<\/td>\n\n \n

    Pacien\u0163ii nou diagnosticati cu NSCLC, \u00een stadii operabile<\/p>\n<\/td>\n\n \n

    oncologie medical\u0103, pneumologie, chirurgie toracic\u0103, precum \u0219i medicul anatomopatolog care a efectuat examenul histopatologic\ufeff<\/span><\/p>\n<\/td>\n\n <\/tr>\n

    Panelul de teste nr. 4\ufeff<\/span><\/p>\n<\/td>\n\n \n

    PD-L1 (22C3 + SP 263+ SP 142)<\/p>\n<\/td>\n\n \n

    IHC\ufeff<\/span><\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103<\/p>\n

     \ufeff<\/span><\/p>\n<\/td>\n\n \n

    Pacien\u0163ii nou diagnosticati cu NSCLC, \u00een stadii operabile<\/p>\n<\/td>\n\n \n

    oncologie medical\u0103, pneumologie, chirurgie toracic\u0103, precum \u0219i medicul anatomopatolog care a efectuat examenul histopatologic\ufeff<\/span><\/p>\n<\/td>\n\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n<\/div>\n\n\n

    \n\n

    \n CANCER DE S\u00c2N <\/p>\n \n

    \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n
    Panel de testare<\/th>\n Teste incluse \u00een panelul de testare<\/th>\n Metoda de lucru<\/th>\n Specimen prob\u0103<\/th>\n Indica\u021bie<\/th>\n Specialit\u0103\u021bi care emit referatul<\/th>\n <\/tr>\n <\/thead>\n \n

    Panelul de teste nr. 1<\/p>\n<\/td>\n\n \n

    HR + HER2 + Ki67<\/p>\n<\/td>\n\n \n

    IHC<\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103<\/p>\n<\/td>\n\n \n

    Se testeaz\u0103 to\u021bi pacien\u0163ii diagnostica\u0163i cu carcinom de s\u00e2n<\/p>\n<\/td>\n\n \n

    oncologie medical\u0103, obstetric\u0103-ginecologie, chirurgie general\u0103<\/p>\n<\/td>\n\n <\/tr>\n

    Panelul de teste nr. 2<\/p>\n<\/td>\n\n \n

    HER2<\/p>\n<\/td>\n\n \n

    SISH\/FISH<\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103<\/p>\n<\/td>\n\n \n

    Se testeaz\u0103 doar pentru pacien\u0163ii pentru care HER2 la IHC (oricare determinare) are valoarea 2+.<\/p>\n<\/td>\n\n \n

    Anatomie Patologica ( medicul responsabil de caz Panelul 1) Atentie: Rezultatul test\u0103rii se transmite de c\u0103tre furnizorul de servicii medicale care a efectuat serviciul de testare at\u00e2t bolnavului, c\u00e2t \u0219i medicului \u00een specialitatea oncologie medical\u0103, obstetric\u0103-ginecologie, chirurgie general\u0103, dup\u0103 caz, \u00een maximum 10 zile lucr\u0103toare de la ob\u021binerea rezultatului, urmare a efectu\u0103rii serviciului de testare prev\u0103zut la panelul de teste nr. 1<\/p>\n<\/td>\n\n <\/tr>\n

    Panelul de teste nr. 3<\/p>\n

     <\/p>\n

     <\/p>\n<\/td>\n\n \n

    BRCA 1 \u015fi 2 – germline \u015fi MLPA<\/p>\n<\/td>\n\n \n

    NGS<\/p>\n<\/td>\n\n \n

    S\u00e2nge EDTA<\/p>\n<\/td>\n\n \n

    Pacien\u0163ii HER2 negativ, cu cancer de s\u00e2n \u00een stadiul local avansat sau metastazat, indiferent de statusul HR<\/p>\n

     <\/p>\n

     <\/p>\n<\/td>\n\n \n

    oncologie medical\u0103<\/p>\n

     <\/p>\n

     <\/p>\n<\/td>\n\n <\/tr>\n

    Panelul de teste nr. 3<\/p>\n

     <\/p>\n

     <\/p>\n<\/td>\n\n \n

    NTRK 1-3<\/p>\n<\/td>\n\n \n

    IHC<\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103<\/p>\n<\/td>\n\n \n

    Pacien\u0163ii HER2 negativ, cu cancer de s\u00e2n \u00een stadiul local avansat sau metastazat, indiferent de statusul HR<\/p>\n

     <\/p>\n

     <\/p>\n<\/td>\n\n \n

    oncologie medical\u0103<\/p>\n

     <\/p>\n

     <\/p>\n<\/td>\n\n <\/tr>\n

    Panelul de teste nr. 3<\/p>\n

     <\/p>\n

     <\/p>\n<\/td>\n\n \n

    PIK3CA – muta\u0163ii hotspot<\/p>\n<\/td>\n\n \n

    PCR\/ NGS<\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103<\/p>\n<\/td>\n\n \n

    Pacien\u0163ii HER2 negativ, cu cancer de s\u00e2n \u00een stadiul local avansat sau metastazat, indiferent de statusul HR<\/p>\n

     <\/p>\n

     <\/p>\n<\/td>\n\n \n

    oncologie medical\u0103<\/p>\n

     <\/p>\n

     <\/p>\n<\/td>\n\n <\/tr>\n

    Panelul de teste nr. 3<\/p>\n

     <\/p>\n

     <\/p>\n<\/td>\n\n \n

    PD-L1 (22C3 + SP 142)<\/p>\n<\/td>\n\n \n

    IHC<\/p>\n<\/td>\n\n \n

    Bloc parafin\u0103<\/p>\n<\/td>\n\n \n

    Pacien\u0163ii HER2 negativ, cu cancer de s\u00e2n \u00een stadiul local avansat sau metastazat, indiferent de statusul HR<\/p>\n

     <\/p>\n

     <\/p>\n<\/td>\n\n \n

    oncologie medical\u0103<\/p>\n

     <\/p>\n

     <\/p>\n<\/td>\n\n <\/tr>\n

    Panelul de teste nr. 4<\/p>\n<\/td>\n\n \n

    BRCA 1 \u015fi 2 \u2013 germline<\/p>\n<\/td>\n\n \n

    NGS \u015fi\/sau MLPA<\/p>\n<\/td>\n\n \n

    S\u00e2nge sau saliv\u0103<\/p>\n<\/td>\n\n \n

    Se testeaz\u0103 doar pacien\u0163ii HER2 negativ, cu carcinom de s\u00e2n \u00een stadiul incipient, cu risc crescut, indiferent de statusul HR.<\/p>\n<\/td>\n\n \n

    oncologie medical\u0103<\/p>\n<\/td>\n\n <\/tr>\n <\/tbody>\n <\/table>\n <\/div>\n<\/div>\n\n\n\n

    \n sus<\/span>\n<\/div>\n\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-templates\/Gutenberg_template_full.php","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"class_list":["post-28377","page","type-page","status-publish","hentry"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.clinica-sante.com\/ro\/wp-json\/wp\/v2\/pages\/28377","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.clinica-sante.com\/ro\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.clinica-sante.com\/ro\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.clinica-sante.com\/ro\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.clinica-sante.com\/ro\/wp-json\/wp\/v2\/comments?post=28377"}],"version-history":[{"count":16,"href":"https:\/\/www.clinica-sante.com\/ro\/wp-json\/wp\/v2\/pages\/28377\/revisions"}],"predecessor-version":[{"id":86032,"href":"https:\/\/www.clinica-sante.com\/ro\/wp-json\/wp\/v2\/pages\/28377\/revisions\/86032"}],"wp:attachment":[{"href":"https:\/\/www.clinica-sante.com\/ro\/wp-json\/wp\/v2\/media?parent=28377"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}